Advertisement

Topics

Personalis, Inc. to Present New Data at the American Association for Cancer Research (AACR) Annual Meeting 2018

09:00 EDT 16 Apr 2018 | Businesswire

Personalis, Inc.

Personalis, Inc., a provider of advanced genomic sequencing and analytics for immuno-oncology, today announced that the company will present four posters at the American Association for Cancer Research (AACR) Annual Meeting being held this year in Chicago, Illinois from April 14-18, 2018.

Following is a list of abstracts that will be presented at the meeting.

                         

Session ID /
Poster Number

      Title & Presenter       Day & Time       Location

PO.BSB01.01
1292

     

Methods of improving accuracy of neoantigen identification for therapeutic and diagnostic use in immuno-oncology
Presenter: Sean Michael Boyle

     

April 16;
8:00am-12:00pm

     

Poster
section 12

PO.BSB01.02
2245

     

Deconvolution of diverse immune cell populations within tumors using ACE Transcriptome
Presenter: Eric Levy

     

April 16;
1:00pm-5:00pm

     

Poster
section 12

PO.MCB09.08
5385

     

Supporting neoantigen discovery and monitoring in plasma through analytical validation of a deep Augmented Content Enhanced (ACE) exome
Presenter: Ravi Alla

     

April 18;
8:00pm-12:00pm

     

Poster
section 17

PO.IM02.04
5710

     

Molecular profiling of anti-PD-1 treated melanoma patients reveals importance of assessing neoantigen burden and tumor escape mechanisms for clinical treatment
Presenter: Sean Michael Boyle

     

April 18;
8:00pm-12:00pm

     

Poster
section 32

                 

About Personalis, Inc.

Personalis, Inc. (www.personalis.com) is a leading precision medicine company focused on advanced NGS-based services for immuno-oncology and cancer for clinical trials and translational research. Personalis also provides DNA and RNA sequencing and data analysis of human genomes.

The Personalis ACE Exome and Transcriptome technology is designed to obtain the most comprehensive and accurate tumor molecular profile and each tumor’s unique immune microenvironment for immuno-oncology applications. The company’s clinical laboratory is GCP compliant, CLIA licensed and CAP accredited. Personalis is differentiated by advanced sequencing assays, algorithms and content for neoantigen characterization, customer regulatory support, and more. Visit our website at www.personalis.com and follow @PersonalisInc.

Personalis
Jennifer Havlek, 650-752-1300
pr@personalis.com
www.personalis.com

NEXT ARTICLE

More From BioPortfolio on "Personalis, Inc. to Present New Data at the American Association for Cancer Research (AACR) Annual Meeting 2018"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

DNA sequencing
DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule. During DNA sequencing, the bases of a small fragment of DNA are sequentially identified from signals emitted as each fragment is re-synthesized from a ...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...